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A B S T R A C T
To evaluate the value of IgG avidity in diagnosis of congenital cytomegalovirus (CMV) infection in newborns and in-
fants we collected serum samples from 40 infants under 12 months of age with suspected congenital CMV infection. Sera
were tested for IgM, IgG and IgG avidity. For 25 of them, virus isolation and/or polymerase chain reaction (PCR) on
urine specimens were performed. Thirteen (32.5%) patients showed the presence of CMV IgM antibodies, 3 (7.5%) had
equivocal IgM result, and 24 (60.0%) patients had IgG antibodies only. Using IgG avidity, CMV infection (low avidity in-
dex-AI) was documented in 61.5% IgM positive and 54.2% IgM negative patients. Eight of nine (88.8%) IgM positive pa-
tients were positive either on virus isolation or PCR. In IgM negative patients, 46.6% urine cultures were positive for
CMV and 66.6% were PCR positive. According to age, IgG avidity demonstrated acute/recent primary CMV infection in
58.8% patients younger than three months compared with 91.7% and 81.8% in 3–6 and 6–12 months old babies, respec-
tively. In conclusion, IgG avidity is useful in diagnosis of CMV infection either in IgM positive or IgM negative children
older than 3 months of age. In infants less than 3 months, transplacentally derived maternal IgG antibodies of high
avidity influence on the IgG avidity result. In these children, CMV infection should be confirmed by direct virologic
methods such as virus isolation or PCR.
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Introduction
Cytomegalovirus (CMV) is the most common cause of
congenital viral infection in developed countries occur-
ring with an incidence of approximately 1% of all live
births1. Congenital CMV infection may be the conse-
quence of primary maternal infection, reactivation or re-
infection with a new strain in seropositive mother2. Trans-
mission of CMV from mother to fetus can occur through-
out the entire gestation period, but infection during the
first trimester of pregnancy has been associated with a
higher incidence of fetal damage3,4. Perinatal infection
can result from contact with genital secretions during
delivery or later in infancy through breast milk2,5,6.
Determination of IgG avidity could help in distin-
guishing primary from past CMV infection7–9. The term
IgG avidity indicates the functional affinity of the IgG
class antibody, i.e. the strength with which the IgG binds
to antigen1,9. During the first weeks of primary infection,
IgG antibodies show a low avidity for the antigen. The
antibody response progressively matures during several
months, and afterwards, IgG avidity remains high10,11.
Full maturation of the IgG antibodies occurs approxi-
mately 3–5 months after primary infection in immuno-
competent subjects7,8. Different studies have shown that
the measurement of IgG avidity is a reliable procedure to
identify primary CMV infection in pregnant women7,9,12–15.
The aim of this study was to evaluate the value of IgG
avidity in diagnosis of congenital CMV infection in new-
borns and infants.
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Patients and Methods
The study was conducted as a part of the project »Vi-
ral infections of the respiratory tract«, approved by the
Ethic Committees of Croatian National Institute of Pub-
lic Health, Zagreb University Children’s Hospital, and
University Hospital for Infectious Diseases.
Patients
Between January 2006 and December 2008, serum
samples from 40 infants under 12 months of age with
clinically suspected congenital CMV infection (develop-
ment delay, neuromuscular disorders, microcephaly, hear-
ing impairment, intracerebral calcifications) were tested
for CMV IgM, IgG and IgG avidity. For 25 of them, urine
specimens were obtained and virus isolation and/or poly-
merase chain reaction (PCR) were performed.
Serology
Anti-CMV IgM and IgG antibodies were detected us-
ing commercial enzyme-linked immunosorbent assay (ETI-
-Cytok M/ETI-Cytok G; Dia Sorin, Saluggia, Italy). The
determination of IgG avidity was carried out with urea as
denaturing agent using commercial diagnostic assay
(Avidity: Anti-CMV Elisa IgG, Euroimmun, Lubeck, Ger-
many). The IgG avidity index (AI) was calculated and ex-
pressed as percentage using the extinction values with
and without urea treatment. The interpretation of AI re-
sults was determinated as follows: AI<40%= low avidity
antibodies indicating primary CMV infection; AI 40–60%
= moderate avidity; AI>60% = high avidity antibodies
indicating past CMV infection.
Isolation and identification of CMV
Five ml of urine specimen was cultured on MRC-5
cells (ATCC, Manassas, VA; USA). The presence of CMV
was detected by observation of cytopathic effect and
identified using CMV immunofluorescence assay (Light
DiagnosticsTM, Temecula, CA).
Molecular diagnostic
Nucleic acids were isolated from urine using a spin
column kit (QIAamp DNA Mini Kit; QIAGEN GmbH,
Hilden). Qualitative real-time PCR was applied to the de-
tection of CMV DNA using a TaqMan Universal PCR
Master Mix kit (Applied Biosystems). To rule out the
presence of PCR inhibitors in individual patient speci-
mens, an internal control kit (TaqMan Exogenous Inter-
nal Positive Control Reagents; Applied Biosystems) was
used. The amplification and detection were performed
with a 7500 Real Time PCR System machine (Applied
Biosystems). Each tube contained a 25 mL reaction mix
which included 2.5 mL of isolated DNA, 0.9 mM forward
primer (5’-CGCTCACATGCAAGAGTTAATCTTT-3’), 0.9
mM reverse primer (5’-AACTCGGTAAGTCTGTTGACA-
TGTATG-3’) and 0.25 mM probe (5’-FAM-CTCTATCT-
GACATACACAAGTAAATCCACGTCCCA-TAMRA-3’).
The reaction mixes were exposed to a 2-min, 50°C – UNG
enzyme activation, a 10-min of denaturation and DNA
polymerase activation at 95°C, and then 45 cycles con-
sisting of 95°C for 15 s and 60°C for 1 min.
Results
Of the 40 sera tested, 13 (32.5%) showed the presence
of CMV IgM antibodies out of which 8 (61.5%) had low
AI, 3 (23.1%) had moderate AI and 2 patients (15.4%)
had high AI. Eight of nine (88.8%) CMV IgM positive pa-
tients were positive either on virus isolation or PCR.
Three patients (7.5%) showed equivocal IgM results and
24 patients (60.0%) showed the presence of CMV IgG an-
tibodies only. In the group with negative IgM antibodies,
thirteen (54.2%) patients had low AI, 5 (20.8%) had mod-
erate AI and 6 patients (25.0%) had high AI. In IgM nega-
tive patients, 7 of the 15 (46.6%) cultures were positive
for CMV and 8 of 12 (66.6%) urine specimens were PCR
positive. In one patient with equivocal IgM results AI
was low, and in two patients AI was high. Two of them
were positive on both isolation and PCR (Table 1).
IgG avidity demonstrated acute/recent primary CMV
infection in 58.8% patients younger than three months
(35.2% showed low AI and 23.6% showed moderate AI).
In contrast, in 3–6 months and 6–12 months age groups,
the percentage of children with primary CMV infection
who showed low or moderate AI was higher (91.7% and
81.8%, respectively). Two twelve-month-old infants with
high AI were nonidentical twins (one of them showed no
IgM antibodies, and the other showed equivocal IgM re-
sult) (Table 2).
Results of virus isolation and PCR in 10 patients with
congenital CMV infection who showed high AI are shown
in Table 3. Two patients had positive IgM, two had equiv-
ocal IgM and six patients had negative IgM antibodies. In
2 infants, CMV was isolated from urine and in 4 infants
CMV genome was detected in urine using PCR. Three in-
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TABLE 1
IgG AVIDITY INDEX IN 40 INFANTS WITH CONGENITAL CMV INFECTION
CMV IgM N(%) LOW AI N(%) Moderate AI N(%) High AI N(%)
Virus isolation
Positive/tested N(%)
PCR Positive/tested
N(%)
Positive 13 (32.5) 8 (61.5) 3 (23.1) 2 (15.4) 4/5 (80.0) 4/4 (100)
Equivocal* 3 (7.5) 1 (33.3) 0 (0) 2 (66.6) 2/2 (100) 2/2 (100)
Negative 24 (60.0) 13 (54.2) 5 (20.8) 6 (25.0) 7/15 (46.6) 8/12 (66.6)
* Samples with absorbance values ranging within ± 10% of the cut-off value
fants were positive on both isolation and PCR. In only
one patient (No 3) results of virus isolation and PCR
were negative; however declining of AI from high to low
in paired sera samples indicated recent CMV infection.
Discussion and Conclusion
The anti-CMV IgG avidity is often used test for sero-
logic confirmation of primary CMV infection, especially
in patients with detectable IgM antibodies. Since mater-
nal IgM antibodies do not cross the placenta, detection of
IgM antibodies in the newborn indicates primary CMV
infection2. However, some congenitally infected infants
do not produce IgM antibodies in response to intrau-
terine infection, or IgM antibody production may be
delayed16. Revello et al.2 detected IgM antibodies in 70%
of congenitally infected babies. Melish and Hanshaw17
found that 50% of culture proven CMV infected new-
borns had IgM antibodies while Schlesinger et al.18 found
that only 2 of 13 (15%) newborns with positive urine
samples detected by PCR were IgM positive. Our results
also indicate a lack of sensitivity of the newborn IgM sta-
tus for the diagnosis of congenital CMV infection. We
demonstrated anti-CMV IgM antibodies in 32.5% pa-
tients. Using IgG avidity, acute or recent CMV infection
was demonstrated in 80% of them.
In this study, 60% of patients had no detectable IgM
antibodies, while acute CMV infection (low AI) was docu-
mented in 54.2% of them. Fifteen (62.5%) urine speci-
mens from IgM negative patients were cultured for CMV
and/or PCR; 46.6% of cultures were positive and 66.6%
samples were PCR positive. Because determination of
IgM antibodies is still considered reasonable for diagno-
sis of CMV infection in congenitally infected babies,
these results emphasizes the importance of IgG avidity
testing in IgM positive as well as in IgM negative pa-
tients with suspected CMV infection. The presence of low
AI in a newborn can be considered a marker of maternal
seroconversion in the second or third trimester of gesta-
tion and, as a consequence, an indicator of congenital
CMV infection. In children older than six months, low AI
indicates that primary CMV infection occurred most
likely perinataly or postnataly. However, in congenitaly
infected babies, IgG avidity maturation may be delayed
(up to 2 years) and therefore, low AI could not rule out
congenital CMV infection in these children19.
Interestingly, we demonstrated primary CMV infec-
tion in 10 babies despite high AI. In all but one patient,
virus isolation and/or PCR confirmed diagnosis of CMV
infection. Seven patients (70%) were under 3 months of
age and high avidity antibodies were transplacentally de-
rived. In two patients (one who was positive by PCR
also), a decline from high to low AI in paired sera con-
firmed a primary CMV infection. In twelve-month-old
nonidentical twins with CMV infection who were PCR
positive IgG avidity increased and reached high AI at the
time of testing. Blackburn et al.20 showed similar results.
They tested a group of twenty-nine 3–12 month old ba-
bies who were CMV IgM and IgG positive. Sixteen of
them (55%) showed low AI indicating primary CMV in-
fection. When the babies were subdivided into age
groups, six of the ten 3-month-old babies (60%) had mod-
erate to high avidity compared with two of the nine 6–12
months old babies.
In conclusion, the results of this study showed that
determination of IgG avidity could be used as a marker
for diagnosis of CMV infection both in IgM positive and
IgM negative children older than 3 months of age. In in-
fants younger than 3 months, transplacentally derived
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TABLE 2
IgG AVIDITY INDEX IN 40 INFANTS WITH CONGENITAL CMV
INFECTION ACCORDING TO AGE
Age N(%)
Low AI
N(%)
Moderate
AI N(%)
High AI
N(%)
<3 months 17 (42.5) 6 (35.2) 4 (23.6) 7 (41.2)
3–6 months 12 (30.0) 10 (83.4) 1 (8.3) 1 (8.3)
6–12 months 11 (27.5) 6 (54.5) 3 (27.3) 2 (18.2)
TABLE 3
RESULTS OF PCR AND VIRUS ISOLATION IN 10 PATIENTS WITH CONGENITAL CMV INFECTION WITH HIGH IgG AVIDITY INDEX
Patient Age CMV IgM IgG avidity index PCR Virus isolation
1 1 mo equivocal high positive positive
2 2 mo negative high/low NT positive
3 2 mo negative high/low negative negative
4 2 mo negative high positive negative
5 2.5 mo positive high positive negative
6 3 mo positive high NT positive
7 3 mo negative high positive negative
8 5 mo negative high positive positive
9* 12 mo equivocal high positive positive
10* 12 mo negative high positive negative
* nonidentical twins, NT – not tested
maternal IgG antibodies of high avidity influence on IgG
avidity result and CMV infection should be confirmed by
direct virologic methods such as virus isolation or PCR.
However, paired serum samples taken several weeks
later could help in the diagnosis of congenital CMV infec-
tion (decline of maternal antibodies and appearance of
low avidity IgG antibodies) in these children.
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ULOGA IgG AVIDITETA U DIJAGNOSTICI INFEKCIJE CITOMEGALOVIRUSOM U
NOVORO\EN^ADI I DOJEN^ADI
S A @ E T A K
Cilj rada bio je odrediti ulogu testa IgG aviditeta u u dijagnostici kongenitalne infekcije citomegalovirusom (CMV) u
novoro|en~adi i dojen~adi. Prikupljeni su uzorci seruma 40 djece mla|e od godinu dana sa suspektom CMV infekcijom i
testirani na prisustvo CMV IgM i IgG protutijela te aviditet IgG protutijela. U 25 djece tako|er je u~injena izolacija
virusa i/ili lan~ana reakcija polimeraze (PCR) iz urina. Trinaest (32,5%) bolesnika imalo je prisutna CMV IgM pro-
tutijela, 3 (7,5%) bolesnika imalo je grani~an IgM nalaz, dok je 24 (60,0%) bolesnika imalo samo CMV IgG protutijela.
Pomo}u IgG aviditeta, akutna CMV infekcija (nizak indeks aviditeta-AI) dokazana je u 61,5% bolesnika s pozitivnim
IgM protutijelima te 54,2% bolesnika s negativnim IgM protutijelima. Osam od 9 (88,8%) IgM pozitivnih bolesnika
imalo je pozitivan nalaz izolacije i/ili PCR. U IgM negativnih bolesnika, virus je izoliran u njih 46,6% dok je 66,6% bilo
PCR pozitivno. S obzirom na dob, testom IgG aviditeta dokazana je primarna CMV infekcija u 58,8% djece mla|e od tri
mjeseca, 91,7% djece u dobi od 3–6 mjeseca te 81,8% djece u dobi od 6–12 mjeseci. U zaklju~ku, test IgG aviditeta mo`e
pomo}i u dijagnostici CMV infekcije u djece starije od 3 mjeseca s pozitivnim kao i negativnim IgM protutijelima. U
djece mla|e od 3 mjeseca, transplacentarno prenesena maj~ina protutijela visokog IgG aviditeta utje~u na rezultat AI.
Stoga u toj dobnoj skupini CMV infekciju treba potvrditi izravnim virolo{kim metodama kao {to je izolacija virusa ili
PCR.
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